Rice Hall James & Associates LLC Invests $1.02 Million in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Rice Hall James & Associates LLC bought a new position in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund bought 53,375 shares of the company's stock, valued at approximately $1,023,000. Rice Hall James & Associates LLC owned 0.07% of Viridian Therapeutics at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. R Squared Ltd bought a new stake in Viridian Therapeutics in the 4th quarter worth approximately $26,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in Viridian Therapeutics in the 3rd quarter worth approximately $149,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in Viridian Therapeutics in the 3rd quarter worth approximately $208,000. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Viridian Therapeutics by 17.0% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,997 shares of the company's stock worth $318,000 after purchasing an additional 2,036 shares during the period. Finally, AlphaCentric Advisors LLC grew its position in Viridian Therapeutics by 20.0% in the 3rd quarter. AlphaCentric Advisors LLC now owns 15,000 shares of the company's stock worth $341,000 after purchasing an additional 2,500 shares during the period.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on VRDN. TD Cowen began coverage on shares of Viridian Therapeutics in a research note on Monday, November 25th. They set a "buy" rating on the stock. Royal Bank of Canada lifted their price target on shares of Viridian Therapeutics from $44.00 to $47.00 and gave the stock an "outperform" rating in a research note on Tuesday, December 17th. HC Wainwright reiterated a "buy" rating and set a $34.00 price target on shares of Viridian Therapeutics in a research note on Monday, December 16th. Wells Fargo & Company reiterated an "equal weight" rating and set a $27.00 price target (down previously from $37.00) on shares of Viridian Therapeutics in a research note on Thursday, December 19th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $38.00 price target on shares of Viridian Therapeutics in a research note on Tuesday, January 7th. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $35.70.

Viridian Therapeutics Price Performance

VRDN stock traded down $0.35 during mid-day trading on Friday, hitting $16.27. The company had a trading volume of 876,859 shares, compared to its average volume of 1,138,710. The company has a market capitalization of $1.29 billion, a price-to-earnings ratio of -3.77 and a beta of 1.32. Viridian Therapeutics, Inc. has a 12-month low of $11.40 and a 12-month high of $27.20. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.04. The company has a 50-day moving average price of $18.66 and a 200 day moving average price of $19.61.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.